Cancers, Vol. 11, Pages 124: Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

Cancers, Vol. 11, Pages 124: Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival Cancers doi: 10.3390/cancers11010124 Authors: Petros Christopoulos Steffen Dietz Martina Kirchner Anna-Lena Volckmar Volker Endris Olaf Neumann Simon Ogrodnik Claus-Peter Heussel Felix J. Herth Martin Eichhorn Michael Meister Jan Budczies Michael Allgäuer Jonas Leichsenring Tomasz Zemojtel Helge Bischoff Peter Schirmacher Michael Thomas Holger Sültmann Albrecht Stenzinger Anaplastic lymphoma kinase (ALK) sequencing can identify resistance mechanisms and guide next-line therapy in ALK+ non-small-cell lung cancer (NSCLC), but the clinical significance of other rebiopsy findings remains unclear. We analysed all stage-IV ALK+ NSCLC patients with longitudinally assessable TP53 status treated in our institutions (n = 62). Patients with TP53 mutations at baseline (TP53mutbas, n = 23) had worse overall survival (OS) than patients with initially wild-type tumours (TP53wtbas, n = 39, 44 vs. 62 months in median, p = 0.018). Within the generally favourable TP53wtbas group, detection of TP53 mutations at progression defined a “converted” subgroup (TP53mutconv, n = 9) with inferior OS, similar to that of TP53mutbas and shorter than that of patients remaining TP53 wild-type (TP53wtprogr, 45 vs. 94 months, p = 0.043). Progression-free survival (PFS) under treatment with tyrosine kinas...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research